CAPTRUST Financial Advisors
KRYS icon

CAPTRUST Financial Advisors’s Krystal Biotech KRYS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305K Buy
1,179
+4
+0.3% +$1.06K ﹤0.01% 2374
2025
Q4 		$290K Buy
+1,175
New +$247K ﹤0.01% 2277
2022
Q3 		– Sell
-155
Closed -$10K – 3127
2022
Q2 		$10K Buy
155
+102
+192% +$6.34K ﹤0.01% 3749
2022
Q1 		$4K Sell
53
-16
-23% -$999 ﹤0.01% 4251
2021
Q4 		$5K Buy
+69
New +$4.02K ﹤0.01% 4074

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAPTRUST Financial Advisors's KRYS Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Krystal Biotech (KRYS) stake by 0.34% in Q1 2026, buying an estimated $1.06K and bringing the position to 1,179 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

CAPTRUST Financial Advisors first reported a position in KRYS in Q4 2021 and has held it in 5 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • CAPTRUST Financial Advisors held 1,179 shares of Krystal Biotech worth $305K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 4 Krystal Biotech shares in Q1 2026, an estimated $1.06K.
  • Krystal Biotech made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2374 holding.
  • CAPTRUST Financial Advisors first reported a position in Krystal Biotech in Q4 2021 and has held it in 5 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.